Cargando…
Possible acute rejection associated with the use of the new anti-hepatitis C virus medications
Hepatitis C virus infection is associated with increased morbidity and mortality. It remains a major challenge for management and treatment, especially in patients with renal transplant. The new direct-acting antiviral agents gave big hopes to both clinicians and patients that they can overcome this...
Autores principales: | Karkout, Khaled A., Al Sherif, Saleema, Hussein, Qutaiba, Albawardi, Alia, Boobes, Yousef |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6335885/ https://www.ncbi.nlm.nih.gov/pubmed/30697524 http://dx.doi.org/10.4103/ajm.AJM_171_17 |
Ejemplares similares
-
Bioenergetic study of murine hepatic tissue treated in vitro with atorvastatin
por: Alfazari, Ali S, et al.
Publicado: (2013) -
Chronic Renal Transplant Rejection and Possible Anti-Proliferative Drug Targets
por: Bhatti, Adnan Bashir, et al.
Publicado: (2015) -
Increased genomic instability following treatment with direct acting anti-hepatitis C virus drugs
por: Hegazy, Mohamed Tharwat, et al.
Publicado: (2018) -
Fibrosing Cholestatic Hepatitis Masquerading Acute Rejection in Hepatitis C Virus–Positive Donor Liver Graft
por: Awan, Rehmat Ullah, et al.
Publicado: (2023) -
Hepatitis C virus and non-Hodgkin’s lymphomas: A minireview
por: Khaled, Hussein, et al.
Publicado: (2017)